Polaris Group
TWSE:6550

Watchlist Manager
Polaris Group Logo
Polaris Group
TWSE:6550
Watchlist
Price: 45.05 TWD -2.17% Market Closed
Market Cap: 34.7B TWD
Have any thoughts about
Polaris Group?
Write Note

Polaris Group
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Polaris Group
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Polaris Group
TWSE:6550
Cash Interest Paid
NT$29.3m
CAGR 3-Years
81%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Beigene Ltd
SSE:688235
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Tanvex BioPharma Inc
TWSE:6541
Cash Interest Paid
NT$57.6m
CAGR 3-Years
12%
CAGR 5-Years
37%
CAGR 10-Years
N/A
No Stocks Found

Polaris Group
Glance View

Market Cap
33.5B TWD
Industry
Biotechnology

In the competitive realm of biotechnology, Polaris Group has carved out a niche by focusing on the research and development of novel cancer therapeutics. Founded with a mission to bring innovative treatments to patients with unmet medical needs, the company has strategically positioned itself within the oncology sector. Polaris Group's approach is to harness the power of immunotherapy, aiming to develop solutions that enhance the immune system's ability to target and destroy cancer cells. This ambitious pursuit leverages cutting-edge technologies and a robust pipeline of investigational drugs, with particular emphasis on engineered drug compounds that can target specific pathways essential for cancer cell survival and proliferation. The key to Polaris Group's financial ecosystem is its revenue generation through strategic partnerships and collaborations with major pharmaceutical companies. By partnering with larger firms, Polaris is able to co-develop its breakthrough therapies, thus sharing the burden of development costs and risks. This model not only facilitates the advancement of their drug candidates but also offers potential revenue streams from milestone payments and royalties upon successful commercialization. Polaris’s business model underscores the significance of collaboration in biotech, where innovative ideas need both scientific expertise and considerable financial backing to transform into viable market solutions, ultimately contributing to the company's profitability and sustained growth in the competitive pharmaceutical landscape.

Intrinsic Value
2.99 TWD
Overvaluation 93%
Intrinsic Value
Price

See Also

What is Polaris Group's Cash Interest Paid?
Cash Interest Paid
29.3m TWD

Based on the financial report for Dec 31, 2023, Polaris Group's Cash Interest Paid amounts to 29.3m TWD.

What is Polaris Group's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 5Y
21%

Over the last year, the Cash Interest Paid growth was 128%. The average annual Cash Interest Paid growth rates for Polaris Group have been 81% over the past three years , 21% over the past five years .

Back to Top